De Novo and PMA Launch Marketing: What You Can and Cannot Say

Most medical device marketing conversations focus on 510(k) clearance. That makes sense, because most devices reach the U.S. market through that pathway. But for companies with De Novo or PMA authorizations, the terminology requirements, the evidence base, and the marketing opportunity are all different. Getting the language wrong carries the same enforcement risk as calling a 510(k) device "approved." Getting it right, particularly for PMA devices, opens legitimate marketing territory that 510(k) language cannot reach.

This article covers both pathways, what each authorization actually means, the correct terminology for each, and where the marketing opportunity and the marketing limits sit. For 510(k) terminology and the cleared-vs-approved foundation, see the companion article in this cluster: https://www.buzzboxmedia.com/blog/fda-cleared-vs-fda-approved-medical-device-marketing/.

De Novo: The "Granted" Pathway

What De Novo authorization actually is

The De Novo pathway was created by Congress in 1997 (as part of the Food and Drug Administration Modernization Act) to address a gap in the 510(k) framework. Some devices are novel: low to moderate risk, but with no legally marketed predicate device, so they cannot use the 510(k) substantial equivalence route. Before De Novo existed, these devices defaulted to Class III status and faced the full PMA requirement, which was disproportionate to their actual risk level.

De Novo provides an alternative classification pathway for these novel devices. The FDA reviews the submission, evaluates the device's risk and the special controls needed to provide reasonable assurance of safety and effectiveness, and, if appropriate, classifies the device into Class I or Class II via a De Novo classification order. Importantly, under 21 U.S.C. 360c(f)(2) a device classified through the De Novo process serves as a predicate device for determining substantial equivalence in future 510(k) submissions by other companies, so the pathway creates a new regulatory category, not just a path for one company.

The FDA's De Novo Classification Request page describes the outcome as receipt of a "De Novo classification order."

The correct marketing terminology for De Novo devices

The FDA's own usage, and the De Novo Classification Process guidance document, uses "granted" to describe the De Novo outcome, in the same way 510(k)s are "cleared" and PMAs are "approved." De Novo authorization is neither a clearance nor an approval in the technical regulatory sense.

Acceptable marketing terms for De Novo devices (as of July 2026):

• "De Novo granted"
• "received De Novo classification from the FDA"
• "FDA De Novo authorized"
• "received a De Novo classification order from the FDA"

Terms that are not accurate and should not be used:

• "FDA cleared" (De Novo is not a 510(k) clearance)
• "FDA approved" (De Novo is not a PMA approval)
• "FDA authorized" alone without the De Novo qualifier (too generic; implies endorsement without identifying the pathway)

The marketing opportunity with De Novo

De Novo authorization carries a meaningful story that is underused in most device marketing. A De Novo device is, by definition, a first-of-kind: there was no predicate when it was authorized. That novelty is both a regulatory fact and a commercial differentiator. Communicating that your device received FDA authorization as the first device in its category is an accurate, impactful claim.

However, the same indications-for-use constraint applies. A De Novo classification order specifies the indications, the patient population, and the intended use environment. Claims must stay within that authorization. The novelty of the pathway does not expand the scope of permitted claims beyond the authorized indications.

PMA: The "Approved" Pathway

What PMA authorization actually is

Premarket Approval (PMA) is the most rigorous regulatory pathway for medical devices in the United States. It is required for Class III devices, those that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury, and that do not have a valid cleared predicate.

Under 21 CFR Part 814, a PMA applicant must provide "valid scientific evidence" that gives the FDA "reasonable assurance" that the device is safe and effective for its intended use. This is a fundamentally different evidentiary standard from 510(k) substantial equivalence. The FDA does not ask whether the PMA device is at least as safe and effective as a predicate. It independently evaluates whether the device is safe and effective in an absolute sense.

The FDA's Premarket Approval page describes the PMA outcome as an "approval order."

The correct marketing terminology for PMA devices

The correct and only accurate term for a device that completed PMA is "FDA approved." This is also one of the few places where the term "approved" is genuinely meaningful in a marketing context: it reflects an independent FDA safety and effectiveness determination that the PMA applicant earned through a substantial evidentiary showing.

Acceptable marketing terms for PMA devices:

• "FDA approved"
• "received Premarket Approval from the FDA"
• "PMA-approved"
• "received FDA approval" (this term means PMA in device regulatory usage)

Terms that are not accurate for PMA devices:

• "FDA cleared" (the PMA pathway is not clearance)
• "510(k) cleared" (obviously inapplicable if the device went through PMA)
• Anything that implies the device merely demonstrated substantial equivalence

The marketing opportunity with PMA

This is the most significant marketing distinction between the pathways. Because the FDA's PMA review independently evaluated the device's safety and effectiveness, a PMA holder can, in appropriate marketing contexts, convey that the FDA approved the device based on a determination that there is reasonable assurance of its safety and effectiveness for its approved indications (the statutory standard under section 515 of the FD&C Act, 21 U.S.C. 360e, and the classification criteria in 21 U.S.C. 360c(a)(1)(C)). This is not simply a regulatory status claim. It reflects the outcome of the most rigorous regulatory review the FDA conducts for devices. It is not, however, a guarantee of individual patient outcomes, and it does not by itself support superiority claims against other devices.

Concrete examples of what this permits:

• "FDA approved based on clinical evidence reviewed by the FDA supporting a reasonable assurance of safety and effectiveness for the approved indications."
• "The FDA's approval of [device] was based on [number]-patient pivotal trial data demonstrating [specific outcome]."
• Describing the scope and quality of the clinical evidence package that supported approval, because that evidence is public record (PMA approval orders and summaries of safety and effectiveness data, or SSEDs, are publicly available on the FDA's PMA database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm).

These are legitimate claims a 510(k) device cannot make, because the 510(k) substantial equivalence determination does not constitute an FDA safety and effectiveness finding. 21 CFR 807.97 states explicitly that the SE determination "does not in any way denote official approval of the device."

The limits that still apply to PMA devices

PMA approval is authorization to market for the approved indications. It is not unlimited marketing authority.

• All marketing claims must stay within the FDA-approved indications for use, not beyond them. Off-label promotion of a PMA device carries the same enforcement risk as off-label promotion of a 510(k) device.
• PMA supplements (required for changes to the approved device) must be filed when modifications to the device, labeling, or intended use require them. Marketing the modified device before the supplement is approved creates the same class of violation as marketing without authorization.
• Superiority claims over other devices still require head-to-head comparative data, regardless of whether your device is PMA-approved and the comparator is 510(k) cleared.
• Patient testimonials and endorsements are subject to the same FTC standards regardless of pathway.

Pathway Comparison: What Each Authorization Lets You Say

Using the PMA Evidence Record in Marketing

One of the underused advantages of PMA approval is that the evidentiary basis for approval becomes public record. The FDA publishes a Summary of Safety and Effectiveness Data (SSED) for most approved PMAs. This document summarizes the clinical and non-clinical data the FDA reviewed and the basis for its approval decision.

Device marketers can reference the SSED to support claims about the clinical evidence base. For example, citing the pivotal trial design, enrollment size, and outcome measures from the SSED as the foundation of marketing claims about the device's evidence base is an accurate, attributable approach to evidence-based marketing. It is also more defensible than general assertions about the device's safety or effectiveness, because the claims are anchored in a specific, publicly available document.

SSEDs are searchable through the FDA's PMA database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm). Locating and reading your SSED, and building a claims matrix derived from its contents, is a practical first step for any PMA device marketing team.

Post-Approval Requirements That Affect Marketing

PMA approval is not a one-time event. Post-approval requirements imposed as conditions of approval can affect what you may say and when.

The FDA may impose post-approval studies as conditions of PMA approval. These studies are conducted after the device is on the market and are intended to collect additional data about device safety and effectiveness in real-world use. If a condition of your PMA approval is a post-approval study, your marketing should not imply that the study's results are in hand if they have not been reported.

PMA supplements are required for changes to the device, its indications, labeling, or manufacturing that fall within the categories described in 21 CFR 814.39. Marketing a device in a way that reflects a changed indication before the supplement is approved creates a gap between your marketing claims and your authorization.

A Note on De Novo as a Predicate

Because a De Novo-authorized device can serve as a predicate for future 510(k) submissions, a De Novo authorization creates a market position that is regulatory as well as commercial. If your De Novo device establishes the first regulatory pathway for a category, future competitors will attempt to clear devices using your authorization as their predicate. This is a publicly visible process (510(k) submissions identify their predicates) and is worth factoring into your competitive marketing strategy.

This regulatory dynamic does not change what you may claim in your marketing, but it does mean that the terms and scope of your De Novo classification order have implications beyond your own product launch.

Working With Buzzbox Media on De Novo and PMA Launches

De Novo and PMA launches are higher-stakes than 510(k) launches in several ways: the evidentiary record is richer and more complex, the commercial window for first-mover advantage can be significant, and the regulatory claims requirements are specific. Building launch marketing that fully uses the evidence base without crossing into impermissible territory requires both regulatory knowledge and marketing execution working in parallel.

Buzzbox Media works exclusively with medical device and healthcare companies. Our over 15 years of focus in medtech means our content process includes regulatory claims review at every stage, not as an add-on but as a built-in step. If your team is preparing for a De Novo or PMA launch, a 30-minute call is a practical starting point. Learn more about our medical device marketing services or book at https://www.buzzboxmedia.com/book.

Related Reading in This Series

• FDA Cleared vs FDA Approved: What You Can Legally Say in Your Medical Device Marketing
• Medical Device Marketing Claims the FDA Allows (and the Ones That Trigger Warning Letters)
• The Post-510(k) Launch Playbook: Your First 90 Days After Clearance
• Can You Market a Medical Device Before FDA Clearance?

Frequently Asked Questions

See the full FAQ below.

Sources Cited

• 21 CFR Part 814, Premarket Approval of Medical Devices: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-814
• 21 CFR 814.39, Amendments to PMA (supplement requirements): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-814/subpart-D/section-814.39
• 21 CFR 807.97 (Misbranding by reference to premarket notification, SE determination language): https://www.law.cornell.edu/cfr/text/21/807.97
• FDA, De Novo Classification Request: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request
• FDA, De Novo Classification Process guidance document: https://www.fda.gov/media/72674/download
• FDA, Premarket Approval (PMA): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma
• FDA, PMA Database (SSEDs and approval orders): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
• 21 U.S.C. 360e (FD&C Act Section 515, Premarket Approval): https://uscode.house.gov/view.xhtml?req=(title:21+section:360e+edition:prelim)
• 21 U.S.C. 360c (FD&C Act Section 513; De Novo classification and predicate rule at 360c(f)(2); classification criteria at 360c(a)(1)(C)): https://www.law.cornell.edu/uscode/text/21/360c
• 21 CFR 860.260 (De Novo classification grant procedure): https://www.law.cornell.edu/cfr/text/21/860.260
• FDA, Device Approvals and Clearances (pathway terminology reference): https://www.fda.gov/medical-devices/products-and-medical-procedures/device-approvals-and-clearances
• Buzzbox Media, FDA Cleared vs FDA Approved companion article: https://www.buzzboxmedia.com/blog/fda-cleared-vs-fda-approved-medical-device-marketing/